Beaumont Financial Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.6M Buy
8,418
+21
+0.3% +$3.61K 0.1% 123
2026
Q1
$1.42M Buy
8,397
+90
+1% +$15.4K 0.1% 133
2025
Q4
$1.4M Sell
8,307
-387
-4% -$62.9K 0.09% 131
2025
Q3
$1.26M Sell
8,694
-275
-3% -$37.5K 0.08% 143
2025
Q2
$1.13M Sell
8,969
-407
-4% -$50K 0.08% 141
2025
Q1
$1.2M Sell
9,376
-55
-0.6% -$7.46K 0.09% 129
2024
Q4
$1.25M Sell
9,431
-13
-0.1% -$1.83K 0.09% 130
2024
Q3
$1.38M Sell
9,444
-130
-1% -$18.8K 0.11% 121
2024
Q2
$1.31M Sell
9,574
-156
-2% -$20.8K 0.11% 126
2024
Q1
$1.34M Sell
9,730
-46
-0.5% -$6.28K 0.11% 122
2023
Q4
$1.33M Sell
9,776
-743
-7% -$90.7K 0.12% 121
2023
Q3
$1.29M Sell
10,519
-25
-0.2% -$3.18K 0.13% 108
2023
Q2
$1.34M Sell
10,544
-251
-2% -$32.6K 0.12% 113
2023
Q1
$1.39M Buy
10,795
+520
+5% +$68.1K 0.14% 100
2022
Q4
$1.35M Sell
10,275
-279
-3% -$36.1K 0.14% 104
2022
Q3
$1.23M Sell
10,554
-48
-0.5% -$5.96K 0.12% 104
2022
Q2
$1.25M Sell
10,602
-3,329
-24% -$395K 0.11% 109
2022
Q1
$1.81M Sell
13,931
-117
-0.8% -$15.2K 0.14% 117
2021
Q4
$2.14M Sell
14,048
-397
-3% -$61.5K 0.16% 96
2021
Q3
$2.33M Sell
14,445
-546
-4% -$91.9K 0.18% 91
2021
Q2
$2.45M Sell
14,991
-231
-2% -$35.6K 0.19% 83
2021
Q1
$2.29M Sell
15,222
-403
-3% -$64K 0.19% 90
2020
Q4
$2.37M Buy
15,625
+852
+6% +$122K 0.21% 87
2020
Q3
$2M Buy
14,773
+4,893
+50% +$664K 0.19% 93
2020
Q2
$1.35M Buy
9,880
+169
+2% +$21.5K 0.14% 114
2020
Q1
$1.05M Sell
9,711
-1,587
-14% -$183K 0.13% 102
2019
Q4
$1.36M Buy
11,298
+323
+3% +$36K 0.13% 109
2019
Q3
$1.09M Sell
10,975
-52
-0.5% -$5.44K 0.11% 115
2019
Q2
$1.2M Sell
11,027
-5,940
-35% -$632K 0.12% 108
2019
Q1
$1.9M Buy
16,967
+380
+2% +$41.7K 0.2% 82
2018
Q4
$1.6M Sell
16,587
-6,565
-28% -$697K 0.26% 63
2018
Q3
$2.82M Sell
23,152
-305
-1% -$35.9K 0.28% 73
2018
Q2
$2.58M Sell
23,457
-334
-1% -$35.7K 0.27% 66
2018
Q1
$2.54M Buy
23,791
+4,723
+25% +$524K 0.28% 71
2017
Q4
$2.04M Sell
19,068
-909
-5% -$97.2K 0.24% 84
2017
Q3
$2.22M Sell
19,977
-549
-3% -$58.7K 0.28% 78
2017
Q2
$2.12M Buy
20,526
+702
+4% +$69.1K 0.28% 80
2017
Q1
$1.94M Buy
19,824
+168
+0.9% +$16.1K 0.27% 82
2016
Q4
$1.74M Sell
19,656
-3,582
-15% -$326K 0.26% 77
2016
Q3
$2.24M Sell
23,238
-4,047
-15% -$385K 0.35% 82
2016
Q2
$2.34M Buy
27,285
+20,598
+308% +$1.85M 0.38% 73
2016
Q1
$765K Sell
6,687
-33,042
-83% -$2.95M 0.12% 85
2015
Q4
$4.48M Sell
39,729
-32,217
-45% -$3.5M 0.74% 47
2015
Q3
$8.3M Hold
71,946
1.2% 35
2015
Q2
$8.3M Sell
71,946
-1,281,621
-95% -$153M 1.2% 35
2015
Q1
$155M Buy
1,353,567
+507,015
+60% +$55.9M 5.4% 1
2014
Q4
$85.6M Buy
846,552
+660,555
+355% +$64.2M 4.12% 3
2014
Q3
$17M Buy
185,997
+64,080
+53% +$5.62M 1.11% 36
2014
Q2
$10.4M Buy
+121,917
New +$9.61M 0.74% 57
2014
Q1
Sell
-2,925
Closed -$221K 143
2013
Q4
$221K Sell
2,925
-150
-5% -$10.6K 0.02% 136
2013
Q3
$215K Buy
+3,075
New +$201K 0.02% 138

Other funds holding IBB

Beaumont Financial Advisors's IBB Position: Q2 2026 in Review

Beaumont Financial Advisors increased its iShares Biotechnology ETF (IBB) stake by 0.25% in Q2 2026, buying an estimated $3.61K and bringing the position to 8,418 shares worth $1.6M. The position accounts for 0.1% of the portfolio, ranked #123.

Beaumont Financial Advisors first reported a position in IBB in Q3 2013 and has held it in 51 quarters since. The position peaked at $155M in Q1 2015. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Beaumont Financial Advisors held 8,418 shares of iShares Biotechnology ETF worth $1.6M as of Q2 2026.
  • Beaumont Financial Advisors bought 21 iShares Biotechnology ETF shares in Q2 2026, an estimated $3.61K.
  • iShares Biotechnology ETF made up 0.1% of Beaumont Financial Advisors's portfolio in Q2 2026, its #123 holding.
  • Beaumont Financial Advisors first reported a position in iShares Biotechnology ETF in Q3 2013 and has held it in 51 quarters since.
  • Beaumont Financial Advisors's iShares Biotechnology ETF position peaked at $155M in Q1 2015.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Beaumont Financial Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.